HRP20041061A2 - Pseudopolymorphic forms of a hiv protease inhibitor - Google Patents

Pseudopolymorphic forms of a hiv protease inhibitor

Info

Publication number
HRP20041061A2
HRP20041061A2 HR20041061A HRP20041061A HRP20041061A2 HR P20041061 A2 HRP20041061 A2 HR P20041061A2 HR 20041061 A HR20041061 A HR 20041061A HR P20041061 A HRP20041061 A HR P20041061A HR P20041061 A2 HRP20041061 A2 HR P20041061A2
Authority
HR
Croatia
Prior art keywords
protease inhibitor
hiv protease
pseudopolymorphic forms
forms
pseudopolymorphic
Prior art date
Application number
HR20041061A
Other languages
English (en)
Inventor
Hans
Daniel
Luc
Original Assignee
Tibotec Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20041061(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals Ltd. filed Critical Tibotec Pharmaceuticals Ltd.
Publication of HRP20041061A2 publication Critical patent/HRP20041061A2/xx
Publication of HRP20041061B1 publication Critical patent/HRP20041061B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Novi pseudopolimorfni oblici (3R, 3aS, 6aR) heksahidro furo [2, 3-b]furan-3-i1(1S, 2R)-3-[[(4-aminofenil) sulfonil]-(izobutil)amino]-1-benzil-2-hidroksipropilkarbamata i postupci za njihovu pripravu prezentirani su ovdje.
HRP20041061AA 2002-05-16 2004-11-12 Pseudopolimorfni oblici inhibitora hiv proteaze HRP20041061B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076929 2002-05-16
PCT/EP2003/050176 WO2003106461A2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor

Publications (2)

Publication Number Publication Date
HRP20041061A2 true HRP20041061A2 (en) 2006-07-31
HRP20041061B1 HRP20041061B1 (hr) 2015-02-27

Family

ID=29724454

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20041061AA HRP20041061B1 (hr) 2002-05-16 2004-11-12 Pseudopolimorfni oblici inhibitora hiv proteaze

Country Status (26)

Country Link
US (8) US7700645B2 (hr)
EP (4) EP1567529B2 (hr)
JP (1) JP4864320B2 (hr)
KR (2) KR101128370B1 (hr)
CN (1) CN100475819C (hr)
AP (1) AP2052A (hr)
AU (2) AU2003271740B2 (hr)
BR (1) BRPI0311176B8 (hr)
CA (1) CA2485834C (hr)
CY (3) CY1117928T1 (hr)
DK (3) DK2767539T3 (hr)
EA (1) EA007120B8 (hr)
ES (4) ES2728735T3 (hr)
HK (1) HK1081969A1 (hr)
HR (1) HRP20041061B1 (hr)
HU (1) HUE034389T2 (hr)
IL (1) IL165140A0 (hr)
LT (1) LT2767539T (hr)
MX (1) MXPA04011427A (hr)
NO (1) NO331477B1 (hr)
NZ (1) NZ536497A (hr)
PL (1) PL215151B1 (hr)
PT (3) PT1567529E (hr)
SI (3) SI2314591T2 (hr)
WO (1) WO2003106461A2 (hr)
ZA (1) ZA200410154B (hr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771780B2 (en) 1998-06-23 2004-04-01 Board Of Trustees Of The University Of Illinois, The Fitness assay and associated methods
HUE034389T2 (en) 2002-05-16 2018-02-28 Janssen Sciences Ireland Uc Pseudopolymorphic forms of an HIV protease inhibitor
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
US7772411B2 (en) 2003-12-23 2010-08-10 Tibotec Pharmaceuticals Ltd. Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
WO2006089942A1 (en) 2005-02-25 2006-08-31 Tibotec Pharmaceuticals Ltd. Protease inhibitor precursor synthesis
DE602007012365D1 (de) * 2006-11-09 2011-03-17 Little Island Co Cork Verfahren zur herstellung von hexahydrofuroä2,3-büfuran-3-ol
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
US20120035142A1 (en) * 2009-01-29 2012-02-09 Mapi Pharma Limited Polymorphs of darunavir
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
CA2776807C (en) * 2009-09-17 2018-10-16 Mylan Laboratories Limited An improved process for the preparation of darunavir
EP2493891A2 (en) 2009-10-30 2012-09-05 Lupin Limited A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
US20110313035A1 (en) * 2009-12-16 2011-12-22 Hetero Research Foundation Polymorphs of darunavir
KR20120123077A (ko) * 2010-01-05 2012-11-07 씨아이피엘에이 엘티디. 다루나비르 다형체 및 그의 제조 방법
WO2011092687A1 (en) 2010-01-28 2011-08-04 Mapi Pharma Hk Limited Process for the preparation of darunavir and darunavir intermediates
CA2799762C (en) 2010-05-20 2018-03-06 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
HUE035241T2 (en) 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination products
WO2013114382A1 (en) 2011-12-05 2013-08-08 Mylan Laboratories Ltd Crystalline darunavir
WO2013108105A2 (en) * 2012-01-18 2013-07-25 Aurobindo Pharma Limited Novel solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
WO2014016660A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited A process for preparation of darunavir
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9346820B2 (en) * 2013-09-11 2016-05-24 Purdue Research Foundation HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092525A1 (en) * 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
ES2926063T3 (es) 2015-03-19 2022-10-21 Mycovia Pharmaceuticals Inc Compuestos antifúngicos y procedimientos de fabricación
EP3496719B1 (en) 2016-08-08 2023-06-14 Hetero Labs Limited A multi-class anti-retroviral composition
WO2018029561A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
US10407438B2 (en) 2016-10-27 2019-09-10 Gilead Sciences, Inc. Crystalline forms of darunavir
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja) 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2127938T3 (es) 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
WO1996026197A1 (en) * 1995-02-22 1996-08-29 Hoechst Pharmaceuticals & Chemicals K.K. Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
CO4940492A1 (es) * 1997-05-29 2000-07-24 Merck & Co Inc Inhibidor de proteasa de vih
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) * 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
AU771780B2 (en) * 1998-06-23 2004-04-01 Board Of Trustees Of The University Of Illinois, The Fitness assay and associated methods
US6225317B1 (en) 1998-11-19 2001-05-01 Dupont Pharmaceuticals Company Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone
AU3485800A (en) 1999-02-12 2000-08-29 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
HUE034389T2 (en) 2002-05-16 2018-02-28 Janssen Sciences Ireland Uc Pseudopolymorphic forms of an HIV protease inhibitor
KR20120123077A (ko) * 2010-01-05 2012-11-07 씨아이피엘에이 엘티디. 다루나비르 다형체 및 그의 제조 방법

Also Published As

Publication number Publication date
NO20045409L (no) 2004-12-10
EP2314591A1 (en) 2011-04-27
CY1119311T1 (el) 2018-02-14
US20140171499A1 (en) 2014-06-19
CA2485834C (en) 2007-07-17
JP4864320B2 (ja) 2012-02-01
KR20100119906A (ko) 2010-11-11
CN1668623A (zh) 2005-09-14
SI2314591T1 (sl) 2014-11-28
PL374321A1 (en) 2005-10-17
AU2003271740A1 (en) 2003-12-31
EA200401503A1 (ru) 2005-06-30
LT2767539T (lt) 2017-09-25
AP2052A (en) 2009-10-05
PT2314591E (pt) 2014-09-19
EA007120B1 (ru) 2006-06-30
SI2767539T1 (sl) 2017-10-30
CY1117928T1 (el) 2017-05-17
US20050250845A1 (en) 2005-11-10
WO2003106461A3 (en) 2004-05-13
DK1567529T3 (da) 2014-09-15
SI2314591T2 (sl) 2021-08-31
NO331477B1 (no) 2012-01-16
KR20050008715A (ko) 2005-01-21
ES2498370T5 (es) 2021-11-24
BRPI0311176B1 (pt) 2019-08-20
AU2003271740B2 (en) 2010-05-13
ES2728735T3 (es) 2019-10-28
ES2638412T3 (es) 2017-10-20
EP2767539B1 (en) 2017-07-12
NZ536497A (en) 2006-08-31
KR101128370B1 (ko) 2012-04-23
US20100204316A1 (en) 2010-08-12
US20130303790A1 (en) 2013-11-14
EP2767539A1 (en) 2014-08-20
PT2767539T (pt) 2017-08-28
US10000504B2 (en) 2018-06-19
DK2767539T3 (en) 2017-09-11
AP2004003191A0 (en) 2004-12-31
DK2314591T3 (da) 2014-09-22
CY1115665T1 (el) 2017-01-25
PT1567529E (pt) 2014-09-09
AU2012205289A1 (en) 2012-08-09
SI1567529T1 (sl) 2014-11-28
WO2003106461A2 (en) 2003-12-24
HRP20041061B1 (hr) 2015-02-27
PL215151B1 (pl) 2013-10-31
EP1567529A2 (en) 2005-08-31
EP1567529B1 (en) 2014-06-18
ES2498370T3 (es) 2014-09-24
HK1081969A1 (en) 2006-05-26
CA2485834A1 (en) 2003-12-24
ES2503551T3 (es) 2014-10-07
JP2005533068A (ja) 2005-11-04
US20180312517A1 (en) 2018-11-01
HUE034389T2 (en) 2018-02-28
DK2314591T4 (da) 2021-05-10
US10858369B2 (en) 2020-12-08
US7700645B2 (en) 2010-04-20
EP1567529B2 (en) 2021-02-24
CN100475819C (zh) 2009-04-08
EP3045460B1 (en) 2019-04-17
BR0311176A (pt) 2005-03-15
EP3045460A1 (en) 2016-07-20
ES2503551T5 (es) 2021-10-28
EP2314591B2 (en) 2021-02-24
EA007120B8 (ru) 2012-03-30
EP2314591B1 (en) 2014-06-18
US20150336980A1 (en) 2015-11-26
US20170260196A1 (en) 2017-09-14
ZA200410154B (en) 2005-12-28
MXPA04011427A (es) 2005-02-17
BRPI0311176B8 (pt) 2021-05-25
US20210179631A1 (en) 2021-06-17
IL165140A0 (en) 2005-12-18
US8518987B2 (en) 2013-08-27
DK1567529T4 (da) 2021-05-10
SI1567529T2 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
HRP20041061B1 (hr) Pseudopolimorfni oblici inhibitora hiv proteaze
CY1119150T1 (el) ΜΕΘΟΔΟΙ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ (3R,3aS,6aR) ΕΞΑΫΔΡΟ-ΦΟΥΡΟ[2,3-b]ΦΟΥΡΑΝ-3-ΟΛΗΣ
ME01059B (me) Proces za pripremanje (3r,3as,6ar)-heksahidrofuro [2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (izobutil) amino]-1-benzil-2- hidroksipropilkarbamata
IL198270A0 (en) Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol
PT1178958E (pt) N-cianometilamidas como inibidores de proteases
BRPI0513899A (pt) moduladores de cinase heterocìclica de anel fundido
LU91710I2 (fr) Pazopanib, facultativement sous forme d'un sel ou d'un solvate pharmaceutiquement acceptable de celui-ci
CY1112028T1 (el) 2-αμινο-7,8-διυδρ0-6η-πυριδο(4,3-d) πυριμιδιν-5-ονες, διαδικασια παρασκευης τους και φαρμακευτικα σκευασματα που τις περιεχουν
ECSP055807A (es) Quinolinilpirrolopirazoles
RS50532B (sr) Kristalni oblik azenapin maleata
AR118270A2 (es) PROCESO PARA LA PREPARACIÓN DEL SOLVATO ETANOLATO DE (1S,2R)-3-[[(4-AMINOFENIL)SULFONIL](ISOBUTIL)AMINO]-1-BENCIL-2-HIDROXIPROPILCARBAMATO DE (3R,3aS,6aR)-HEXAHIDROFURO[2,3-B]FURAN-3-ILO
DE602004021640D1 (de) Verfahren zur herstellung von (1s,2r)-3-ää(4-aminophenyl)sulfonylü(isobutyl)aminoü-1-benzyl-2-hydroxypropylcarbamidsäure-(3r,3as,6ar)-hexahydrofuroä2,3-büfuran-3-ylester
AU2003287038A1 (en) METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO (2, 3-b) FURAN AND RELATED COMPOUNDS
BR112021023607A2 (pt) Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase
MEP39608A (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
BR0311329A (pt) Camptotecinas com um anel de lactona modificado
ATE535530T1 (de) 7-substituierte camptothecin- und camptothecin- analoga und herstellungsverfahren dafür
ATE281455T1 (de) Oxindolderivate
DK1606307T3 (da) Östrieno(3,2-b)/(3,4-b)pyrrolderivater egnede som modulatorer for östrogenreceptorer
UA50178A (uk) Спосіб одержання дріжджового тіста

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: JANSSEN SCIENCES IRELAND UC, IE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190417

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200422

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210514

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220516

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20230516